These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 19482866

  • 1. Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study.
    Stelmasiak Z, Solski J, Nowicki J, Jakubowska B, Ryba M, Grieb P.
    Mult Scler; 2009 Jun; 15(6):767-70. PubMed ID: 19482866
    [Abstract] [Full Text] [Related]

  • 2. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
    Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ, CLARITY Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):416-26. PubMed ID: 20089960
    [Abstract] [Full Text] [Related]

  • 3. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
    Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Hamlett A, Miret M, Weiner J, Viglietta V, Musch B, Greenberg SJ, CLARITY Study Group.
    Mult Scler; 2011 May 04; 17(5):578-93. PubMed ID: 21228029
    [Abstract] [Full Text] [Related]

  • 4. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
    Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett A, Viglietta V, Greenberg S, CLARITY study group.
    Lancet Neurol; 2011 Apr 04; 10(4):329-37. PubMed ID: 21397565
    [Abstract] [Full Text] [Related]

  • 5. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
    Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, Vermersch P, Casset-Semanaz F, Scaramozza M, oral cladribine for early MS (ORACLE MS) Study Group.
    Lancet Neurol; 2014 Mar 04; 13(3):257-67. PubMed ID: 24502830
    [Abstract] [Full Text] [Related]

  • 6. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.
    Mult Scler; 2010 Jul 04; 16(7):848-54. PubMed ID: 20488825
    [Abstract] [Full Text] [Related]

  • 7. Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine.
    Bartosik-Psujek H, Belniak E, Mitosek-Szewczyk K, Dobosz B, Stelmasiak Z.
    Acta Neurol Scand; 2004 Jun 04; 109(6):390-2. PubMed ID: 15147461
    [Abstract] [Full Text] [Related]

  • 8. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis.
    Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E.
    Proc Assoc Am Physicians; 1999 Jun 04; 111(1):35-44. PubMed ID: 9893155
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
    Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P.
    Mult Scler; 2018 Oct 04; 24(12):1594-1604. PubMed ID: 28870107
    [Abstract] [Full Text] [Related]

  • 10. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, Sørensen PS, Maas-Enriquez M, Sommerauer B, Hanna K, PRIVIG Study Group, UBC MS/MRI Research Group.
    Neurology; 2008 Jul 22; 71(4):265-71. PubMed ID: 18645164
    [Abstract] [Full Text] [Related]

  • 11. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
    Comi G, Cook S, Giovannoni G, Rieckmann P, Sørensen PS, Vermersch P, Galazka A, Nolting A, Hicking C, Dangond F.
    Mult Scler Relat Disord; 2019 Apr 22; 29():168-174. PubMed ID: 30885375
    [Abstract] [Full Text] [Related]

  • 12. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
    Singer B, Ross AP, Tobias K.
    Int J Clin Pract; 2011 Aug 22; 65(8):887-95. PubMed ID: 21679286
    [Abstract] [Full Text] [Related]

  • 13. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
    Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, Hicking C, Galazka A, Sylvester E.
    Mult Scler Relat Disord; 2019 Apr 22; 29():157-167. PubMed ID: 30885374
    [Abstract] [Full Text] [Related]

  • 14. An update on cladribine for relapsing-remitting multiple sclerosis.
    Holmøy T, Torkildsen Ø, Myhr KM.
    Expert Opin Pharmacother; 2017 Oct 22; 18(15):1627-1635. PubMed ID: 28858531
    [Abstract] [Full Text] [Related]

  • 15. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
    Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R, GALA Study Group.
    Ann Neurol; 2013 Jun 22; 73(6):705-13. PubMed ID: 23686821
    [Abstract] [Full Text] [Related]

  • 16. Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis.
    Terranova N, Hicking C, Dangond F, Munafo A.
    Clin Pharmacokinet; 2019 Mar 22; 58(3):325-333. PubMed ID: 29992396
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
    Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan KW, Rieckmann P, Comi G, Dangond F, Hicking C, Vermersch P.
    Mult Scler; 2019 May 22; 25(6):819-827. PubMed ID: 29716436
    [Abstract] [Full Text] [Related]

  • 18. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
    Ali S, Paracha N, Cook S, Giovannoni G, Comi G, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Greenberg S, Scott DA, Joyeux A, CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) Study Group.
    Clin Drug Investig; 2012 Jan 01; 32(1):15-27. PubMed ID: 22017519
    [Abstract] [Full Text] [Related]

  • 19. Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
    Janiec K, Wajgt A, Kondera-Anasz Z.
    Med Sci Monit; 2001 Jan 01; 7(1):93-8. PubMed ID: 11208501
    [Abstract] [Full Text] [Related]

  • 20. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.